Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Share-based Compensation (2021 - 2024)

Opus Genetics (IRD) has disclosed Share-based Compensation for 8 consecutive years, with -$2.5 million as the latest value for Q4 2023.

  • On a quarterly basis, Share-based Compensation fell 695.28% to -$2.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $275000.0, a 87.63% decrease, with the full-year FY2024 number at $245000.0, down 10.91% from a year prior.
  • Share-based Compensation was -$2.5 million for Q4 2023 at Opus Genetics, down from $2.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q3 2023 to a low of -$2.5 million in Q4 2023.
  • A 3-year average of $347100.0 and a median of $461500.0 in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 177.82% in 2022, then tumbled 2059.26% in 2023.
  • Opus Genetics' Share-based Compensation stood at $478000.0 in 2021, then fell by 11.3% to $424000.0 in 2022, then plummeted by 695.28% to -$2.5 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Share-based Compensation are -$2.5 million (Q4 2023), $2.5 million (Q3 2023), and -$529000.0 (Q2 2023).